Denosumab‐Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Bone and Mineral Research"
DOI: 10.1002/jbmr.4625
Abstract: We interest the recent article by Everts-Graber and colleagues regarding the higher risk of osteonecrosis of the jaw (ONJ) under denosumab compared to bisphosphonates (BPs) in patients with osteoporosis. (1) It was also reported that… read more here.
Keywords: denosumab; denosumab related; bone; teriparatide treatment ... See more keywords
Persistence of and switches from teriparatide treatment among women and men with osteoporosis in the real world: a claims database analysis
Sign Up to like & getrecommendations! Published in 2018 at "Archives of Osteoporosis"
DOI: 10.1007/s11657-018-0466-0
Abstract: SummaryThis study investigated the real-world persistence rate and switches of teriparatide-treated patients using a claims database in Japan. The persistence rate of teriparatide at 12 months was 34.9%, and approximately one-third of the patients were not… read more here.
Keywords: real world; teriparatide treatment; treatment; claims database ... See more keywords
Weekly teriparatide treatment increases vertebral body strength by improving cortical shell architecture in ovariectomized cynomolgus monkeys.
Sign Up to like & getrecommendations! Published in 2019 at "Bone"
DOI: 10.1016/j.bone.2019.01.006
Abstract: Weekly teriparatide treatment is reported to reduce the incidence of osteoporotic vertebral fractures. However, the effect of weekly teriparatide on cortical bone has not been clarified. This study aimed to examine the effects of weekly… read more here.
Keywords: weekly teriparatide; cortical shell; teriparatide; teriparatide treatment ... See more keywords
P0902DAILY TERIPARATIDE TREATMENT AND PHARMACOKINETICS IN HEMODIALYSIS PATIENTS WITH LOW BONE MASS
Sign Up to like & getrecommendations! Published in 2020 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfaa142.p0902
Abstract: Daily 20µg teriparatide (PTH1-34) is an osteoanabolic agent approved for use treating osteoporosis. However, there are few reports about concerning use of this agent in hemodialysis patients. We conducted an observational study, single centre study… read more here.
Keywords: hemodialysis; teriparatide treatment; patients low; treatment ... See more keywords
Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
Sign Up to like & getrecommendations! Published in 2017 at "Asian Spine Journal"
DOI: 10.4184/asj.2017.11.2.272
Abstract: Study Design Retrospective case series. Purpose The purpose of this study was to determine whether discontinuing teriparatide treatment and replacing it with bisphosphonate treatment maintains the volume of the fusion mass after posterolateral fusion (PLF)… read more here.
Keywords: discontinuing teriparatide; teriparatide treatment; fusion mass; treatment ... See more keywords